Evidence map›Paper›PMID 36705269›Full record

ArticleThe Journal of infectious diseases2023

Association of Culturable-Virus Detection and Household Transmission of SARS-CoV-2, California and Tennessee, 2020-2022.

Jessica E Deyoe, J Daniel Kelly, Carlos G Grijalva, Gaston Bonenfant, Scott Lu, Khamal Anglin, Miguel Garcia-Knight, Jesus Pineda-Ramirez, Melissa Briggs Hagen, Sharon Saydah and 24 more

Open access · hybridAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in The Journal of infectious diseases, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed, 1 pooled it
1.6field-weighted citation impact, top 19% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 1 synthesis or guideline pooled it, 8 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Article
  5. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

34 authors at 4 institutions in 1 country.

Jessica E DeyoeCenters for Disease Control and Prevention, Atlanta, Georgia, USA.ORCID 0000-0001-6702-8698
J Daniel KellyDepartment of Epidemiology and Biostatistics, University of California, San Francisco, California, USA.
Carlos G GrijalvaVanderbilt University Medical Center, Nashville, Tennessee, USA.
Gaston BonenfantCenters for Disease Control and Prevention, Atlanta, Georgia, USA.
Scott LuDepartment of Epidemiology and Biostatistics, University of California, San Francisco, California, USA.
Khamal AnglinDepartment of Epidemiology and Biostatistics, University of California, San Francisco, California, USA.
Miguel Garcia-KnightDepartment of Microbiology and Immunology, University of California, San Francisco, California, USA.
Jesus Pineda-RamirezDepartment of Epidemiology and Biostatistics, University of California, San Francisco, California, USA.
Melissa Briggs HagenCenters for Disease Control and Prevention, Atlanta, Georgia, USA.
Sharon SaydahCenters for Disease Control and Prevention, Atlanta, Georgia, USA.
Glen R AbediCenters for Disease Control and Prevention, Atlanta, Georgia, USA.
Sarah A GoldbergDepartment of Epidemiology and Biostatistics, University of California, San Francisco, California, USA.
Michel TassettoDepartment of Microbiology and Immunology, University of California, San Francisco, California, USA.
Amethyst ZhangDepartment of Microbiology and Immunology, University of California, San Francisco, California, USA.
Kevin C DonohueSchool of Medicine, University of California, San Francisco, California, USA.
Michelle C DavidsonSchool of Medicine, University of California, San Francisco, California, USA.
Ruth Diaz SanchezDepartment of Epidemiology and Biostatistics, University of California, San Francisco, California, USA.
Manuella DjomaleuDepartment of Microbiology and Immunology, University of California, San Francisco, California, USA.
Sujata MathurDepartment of Epidemiology and Biostatistics, University of California, San Francisco, California, USA.
Joshua R ShakSan Francisco VA Medical Center, San Francisco, California, USA.
Steven G DeeksDivision of HIV, Infectious Disease, and Global Medicine, University of California, San Francisco, California, USA.
Michael J PelusoDivision of HIV, Infectious Disease, and Global Medicine, University of California, San Francisco, California, USA.
Charles Y ChiuDivision of Infectious Diseases, University of California, San Francisco, California, USA.
Yuwei ZhuVanderbilt University Medical Center, Nashville, Tennessee, USA.
Natasha B HalasaVanderbilt University Medical Center, Nashville, Tennessee, USA.
James D ChappellVanderbilt University Medical Center, Nashville, Tennessee, USA.
Alexandra MellisCenters for Disease Control and Prevention, Atlanta, Georgia, USA.
Carrie ReedCenters for Disease Control and Prevention, Atlanta, Georgia, USA.ORCID 0000-0001-7944-7638
Raul AndinoDepartment of Microbiology and Immunology, University of California, San Francisco, California, USA.
Jeffrey N MartinDepartment of Epidemiology and Biostatistics, University of California, San Francisco, California, USA.
Bin ZhouCenters for Disease Control and Prevention, Atlanta, Georgia, USA.
H Keipp TalbotVanderbilt University Medical Center, Nashville, Tennessee, USA.
Claire M MidgleyCenters for Disease Control and Prevention, Atlanta, Georgia, USA.
Melissa A RolfesCenters for Disease Control and Prevention, Atlanta, Georgia, USA.
University of California, San Francisco · USCenters for Disease Control and Prevention · USVanderbilt University Medical Center · USSan Francisco VA Medical Center · US

Funding

Vanderbilt Institute for Clinical and Translational Research (VICTR) -Identifying correlates of functional immunity in SARS-CoV-2 convalescent plasmaUL1TR002243 · NCATS · VANDERBILT UNIVERSITY MEDICAL CENTER · PI Paul A. Harris, Wesley H Self · 2017 to 2026
$130.7M
Training in HIV Translational ResearchT32AI060530 · NIAID · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI Diane V Havlir · 2005 to 2026
$6.4M
Household Transmission of Influenza Viruses in the Community-COVID 19 SupplementU01IP001083 · IP · VANDERBILT UNIVERSITY MEDICAL CENTER · PI GRIJALVA, CARLOS G, TALBOT, HELEN KEIPP · 2017 to 2019
$2.2M
Characterizing the virologic and immunologic signatures of HIV exceptional controlK23AI157875 · NIAID · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI PELUSO, MICHAEL JOSEPH · 2021 to 2025
$927k
Mentoring in transmission of influenza and strategies for preventionK24AI148459 · NIAID · VANDERBILT UNIVERSITY MEDICAL CENTER · PI GRIJALVA, CARLOS G · 2020 to 2024
$893k
Understanding the epidemiology and natural history of unrecognized Ebola virus infectionK23AI146268 · NIAID · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI KELLY, JOHN DANIEL · 2019 to 2022
$748k
Intramural CDC HHS CC999999NCATS NIH HHS UL1 TR002243NCEZID CDC HHS U01 CK000539NCIRD CDC HHS U01 IP001083NIAID NIH HHS K23 AI146268NIAID NIH HHS K23 AI157875NIAID NIH HHS K24 AI148459NIAID NIH HHS L30 AI126521NIAID NIH HHS L30 AI147159NIAID NIH HHS T32 AI060530
6 · The paper itself

Abstract

From 2 severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) household transmission studies (enrolling April 2020 to January 2022) with rapid enrollment and specimen collection for 14 days, 61% (43/70) of primary cases had culturable virus detected ≥6 days post-onset. Risk of secondary infection among household contacts tended to be greater when primary cases had culturable virus detected after onset. Regardless of duration of culturable virus, most secondary infections (70%, 28/40) had serial intervals <6 days, suggesting early transmission. These data examine viral culture as a proxy for infectiousness, reaffirm the need for rapid control measures after infection, and highlight the potential for prolonged infectiousness (≥6 days) in many individuals.

Indexed as

COVID-19SARS-CoV-2CaliforniaFamily CharacteristicsHumansTennesseehousehold transmissionSARS-CoV-2secondary infection riskviral culture

Identifiers

PMID36705269
PMCPMC10266938
OpenAlexW4318263699

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.